GRI Bio Inc - Company Review
GRI Bio Inc - Company ReviewSummary
GRI Bio Inc (GRI Bio) is a biotech company that develops and manufactures therapies for inflammatory diseases. The company develops Natural Killer T cell based therapies for the treatment of liver disease and autoimmune disoders. Its lead candidate GRI-0621, a novel oral therapeutic for liver disease is an inhibitor of type I NKT cells. GRI Bio’s other pipeline products include GRI 101, GRI-0621, GRI 201, GRI 202 and GRI 203 are under preclinical stage of development for the treatment of chronic liver disease and ALD. Its research and development facility is located at the Torrey Pines Institute of Molecular Studies. GRI Bio is headquartered in La Jolla, California, the US.
This comprehensive company report of GRI Bio Inc provides you with company's businesses and operations information.
The profile contains critical company information including,
- Company Overview - A detailed description of the company's operations and business divisions.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
GlobalData is a one-stop solution for actionable insight into the pharmaceutical and medical device sectors. Together with the best team of researchers, analysts, epidemiologists and consultants, and an unmatched suite of proprietary databases, we provide high-quality, accurate and transparent insight that can help you achieve growth and increase business value.
Our valuable research and consulting solutions ensure you stay at the forefront of the industry by integrating accurate market forecasts and healthcare analytics on the latest trends and developments. Among other benefits, our informed healthcare industry perspectives have assisted businesses based across the pharmaceuticals, biotechnology and medical equipment markets in making strategic decisions that have increased the value of their products and services.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.